Skip to search formSkip to main contentSkip to account menu

GTI2040

Known as: GTI 2040, GTI-2040 
A substance being studied in the treatment of cancer. It blocks the production of a protein called ribonucleotide reductase, which helps cells make… 
National Institutes of Health

Related topics

Related topics

8 relations
Gene Expression RegulationNCIt Antineoplastic Agent TerminologyRNA BindingTranslational Repression

Broader (1)

Oligodeoxyribonucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study
Abstract We performed a phase I study of GTI-2040, an antisense oligonucleotide against ribonucleotide reductase mRNA, on a novel… 
2016
2016
“Impacto de acciones de mejora desarrolladas a partir de indicadores de calidad en el tratamiento de las intoxicaciones agudas pediátricas” "Impact of improvement actions developed from quality…
Objetivo: Analizar el impacto de la aplicacion de medidas de mejora implementadas a partir de la evaluacion de indicadores de… 
2011
2011
Heparin‐induced thrombocytopenia: evaluation of IgG and IgGAM ELISA assays
Background:  Heparin‐induced thrombocytopenia (HIT) is a rare complication of heparin therapy resulting from antibody production… 
2011
2011
Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2
PurposeGTI-2040, a 20-mer phosphorothioate oligonucleotide, was designed to hybridize to the mRNA sequence of human… 
2008
2008
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma
BackgroundFluoropyrimidine based therapy has modest activity in patients with metastatic renal carcinoma and inhibition of… 
2006
2006
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC).
13015 Background: Despite initial responses to chemotherapy, median survival in HRPC remains a dismal 18 mos. Novel therapeutic… 
2006
2006
Pharmacokinetics, pharmacodynamics and metabolism of GTI-2040, a phosphorothioate oligonucleotide targeting R2 subunit of ribonucleotide reductase
2005
2005
Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors
7253 Background: Median survival in advanced NSCLC with systemic therapy is 8 to 10 months, with modest benefits from 1st-, 2nd… 
2004
2004
457 Interim evaluation of a multi-institution phase I/II study of antisense oligonucleotide GTI-2040 (G) and capecitabine (C) in patients with metastatic renal cell carcinoma (mRCC)
2001
2001
GTI-2040. Lorus Therapeutics.
Loris Therapeutics (formerly GeneSense Therapeutics) is developing the antisense oligonucleotide GTI-2040, directed against the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)